Literature DB >> 16000574

A haplotype analysis of HER-2 gene polymorphisms: association with breast cancer risk, HER-2 protein expression in the tumor, and disease recurrence in Korea.

Wonshik Han1, Daehee Kang, Jong Eun Lee, In Ae Park, Ji-Yeob Choi, Kyung-Mu Lee, Ji Yeon Bae, Sook Kim, Eun-Soon Shin, Jeong Eon Lee, Hyuk-Jae Shin, Seok Won Kim, Sung-Won Kim, Dong-Young Noh.   

Abstract

PURPOSE: A single-nucleotide polymorphism (SNP) in codon 655 of HER-2 has been extensively studied with inconclusive results. The purpose of this study was to investigate the association between common variants of HER-2 and breast cancer risk, HER-2 expression, and survival using a haplotype-based stepwise approach. EXPERIMENTAL
DESIGN: Twenty-nine SNPs listed in the National Center for Biotechnology Information database were screened to identify novel polymorphisms of HER-2 gene in 90 healthy Korean women. Six of 29 SNPs were polymorphic and had greater than 10% of minor allele frequencies. Using these six SNPs, linkage disequilibrium and haplotype patterns were characterized. We tested association between the haplotypes and breast cancer in a large case-control study (n=1,039 cases and 995 controls). Six-hundred two breast cancer patients with follow-up at least 24 months were analyzed for outcome in relation to haplotype. Expression of HER-2 protein was determined by immunohistochemistry in 1,094 cases of invasive breast cancer.
RESULTS: All six SNPs showed a strong linkage disequilibrium pattern and were considered to belong to one haplotype block. Two haplotype-tagging SNPs (I655V and P1170A) for three common haplotypes (>5%) were genotyped in cases and controls. The haplotypes and individual SNPs were not associated with breast cancer risk. In patients with at least one copy of haplotype I (the most common haplotype), HER-2 expression was 1.5 times higher (P = 0.009) and the prognosis was worse (P = 0.032) compared with patients without having that haplotype.
CONCLUSIONS: Our results suggest that the currently identified genetic polymorphisms of HER-2 are not associated with an increased risk of breast cancer in Korean women, whereas one haplotype does affect protein expression of the tumor and disease outcome.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16000574     DOI: 10.1158/1078-0432.CCR-04-2208

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  14 in total

1.  Breast Cancer-Related Low Penetrance Genes.

Authors:  Daehee Kang; Ji-Yeob Choi
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

2.  HER2 Pro1170Ala polymorphism is associated with decreased survival rate in HER2-negative breast cancer.

Authors:  Pilei Si; Ye Xu; Tao Ouyang; Jinfeng Li; Tianfeng Wang; Zhaoqing Fan; Tie Fan; Benyao Lin; Yuntao Xie
Journal:  Oncol Lett       Date:  2017-03-17       Impact factor: 2.967

3.  HapMap-based study of CIP2A gene polymorphisms and HCC susceptibility.

Authors:  Yuchun Li; Kaijuan Wang; Liping Dai; Peng Wang; Chunhua Song; Jianxiang Shi; Pengfei Ren; Hua Ye; Jianying Zhang
Journal:  Oncol Lett       Date:  2012-05-23       Impact factor: 2.967

4.  Heritable variation of ERBB2 and breast cancer risk.

Authors:  Joan P Breyer; Melinda E Sanders; David C Airey; Qiuyin Cai; Brian L Yaspan; Peggy A Schuyler; Qi Dai; Fouad Boulos; Maria G Olivares; Kevin M Bradley; Yu-Tang Gao; David L Page; William D Dupont; Wei Zheng; Jeffrey R Smith
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-03-31       Impact factor: 4.254

5.  Detection of HER2 polymorphism and expression using circulating DNA and RNA as a tool in lung adenocarcinoma patients: a case control study.

Authors:  Masroor Mirza; Jamsheed Javid; Prasant Yadav; Anant Mohan; Prakash Chandra Ray; Alpana Saxena
Journal:  Ann Transl Med       Date:  2016-06

6.  Sequence variants and haplotype analysis of cat ERBB2 gene: a survey on spontaneous cat mammary neoplastic and non-neoplastic lesions.

Authors:  Sara Santos; Estela Bastos; Cláudia S Baptista; Daniela Sá; Christophe Caloustian; Henrique Guedes-Pinto; Fátima Gärtner; Ivo G Gut; Raquel Chaves
Journal:  Int J Mol Sci       Date:  2012-03-02       Impact factor: 6.208

7.  Comprehensive analysis of the ATM, CHEK2 and ERBB2 genes in relation to breast tumour characteristics and survival: a population-based case-control and follow-up study.

Authors:  Kristjana Einarsdóttir; Lena U Rosenberg; Keith Humphreys; Carine Bonnard; Juni Palmgren; Yuqing Li; Yi Li; Kee S Chia; Edison T Liu; Per Hall; Jianjun Liu; Sara Wedrén
Journal:  Breast Cancer Res       Date:  2006       Impact factor: 6.466

8.  Pro1170 Ala polymorphism in HER2-neu is associated with risk of trastuzumab cardiotoxicity.

Authors:  Sasha E Stanton; Maureen M Ward; Paul Christos; Rachel Sanford; Christina Lam; Marta V Cobham; Diana Donovan; Ronald J Scheff; Tessa Cigler; Anne Moore; Linda T Vahdat; Maureen E Lane; Ellen Chuang
Journal:  BMC Cancer       Date:  2015-04-11       Impact factor: 4.430

9.  Potential Gene Association Studies of Chemotherapy-Induced Cardiotoxicity: A Systematic Review and Meta-Analysis.

Authors:  Xinyu Yang; Guoping Li; Manke Guan; Aneesh Bapat; Qianqian Dai; Changming Zhong; Tao Yang; Changyong Luo; Na An; Wenjing Liu; Fan Yang; Haie Pan; Pengqian Wang; Yonghong Gao; Ye Gong; Saumya Das; Hongcai Shang; Yanwei Xing
Journal:  Front Cardiovasc Med       Date:  2021-06-04

10.  The genetic polymorphisms of HER-2 and the risk of lung cancer in a Korean population.

Authors:  Uk Hyun Jo; Sle Gi Lo Han; Jae Hong Seo; Kyong Hwa Park; Jae Won Lee; Hyo Jung Lee; Jeong Seon Ryu; Yeul Hong Kim
Journal:  BMC Cancer       Date:  2008-12-04       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.